4
Changes in Ownership
Atea Pharmaceuticals, Inc. Filed Acc 0000950170-24-010968
Chief Commercial Officer sold 11,819 shares at $3.84 ($45,420)
- Chief Commercial Officer acquired 33,334 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Vavricka John Chief Commercial Officer | 2024-01-31 | Option exercise | +33,334 | 33,334 | D | ||
| Vavricka John Chief Commercial Officer | 2024-02-01 | Sale | −11,819 | $3.84 | $45,420 | 21,515 | D |
| Derivatives | |||||||
| Vavricka John Chief Commercial Officer | 2024-01-31 | Option exercise · Restricted Stock Units | −33,334 | 66,666 | D | ||
| Vavricka John Chief Commercial Officer | 2024-01-31 | Grant or award · Stock Option (Right to Buy) | +132,800 | 132,800 | D | ||
| Open-market sales · 11,819 sh · avg $3.84 · $45,420 | |||||||
Loading xslF345X05/ownership.xml…